All In Biotech

Drug Trial Radar · NCT07736950

A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma

An ALLG International Randomised Phase III Trial of Surovatamig Versus Involved Site Radiotherapy With or Without Rituximab in Limited Stage Nodal Follicular Lymphoma

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Jan 12, 2027

Primary completion

Jan 13, 2035

Study completion Jan 13, 2035

Sponsor

Lead sponsor
Australasian Leukaemia and Lymphoma GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if surovatamig works better than standard of care involved-site radiotherapy (ISRT) with or without rituximab to treat patients with limited-stage follicular lymphoma. It will also learn about the safety of the drug. The main questions it aims to answer is whether surovatamig can produce deeper and more durable responses, reduce the risk of disease relapse, and improve event-free survival. Participants will: 1\) Take surovatamig for 4 cycles. The first cycle will have a dose ramp up in 3 steps over a period of 14 days. Cycle 2-4 are for 28 days with drug administered every fortnight. OR 2a) Undergo radiotherapy only for 3 weeks OR 2b) Radiotherapy + rituximab weekly for 6 doses (6 weeks) Visit the clinic once every cycle, at the end of treatment, and be monitored every 3 months in year 1, every 6 months in year 2, and once a year from year 3-5 for checkups and tests.

Conditions

  • Follicular Lymphoma

Interventions

  • SurovatamigDrug

    Surovatamig is supplied as a concentrate for solution for intravenous administration (2mg/mL).

  • Involved Site Radiotherapy (ISRT)Radiation

    24 Gray of ISRT

  • Involved-Site Radiotherapy (ISRT) + RituximabRadiation

    Involved-Site Radiotherapy (ISRT) at 24Gy with 6 doses of rituximab administered weekly by intravenous (IV) at 375 mg/m\^2. 1 week = 1 cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event Free SurvivalTime frame: Time from date of randomisation until disease progression until end of 5 year follow up.
  2. Event Free SurvivalTime frame: Time from date of randomisation to death from any cause, initiation of new anti-lymphoma treatment or disease progression until end of 10 year follow up. Assessment will be performed at end of treatment, every 3 months in year 1, every 6 months in year 2

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.